Dark

Check out our API

ACOR
Acorda Therapeutics, Inc.
stock NASDAQ

Inactive

Apr 11, 2024

0.6610USD-24.023%(-0.2090)416,928

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-0.87)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 4, 2022

07:11AM EST Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference Business Wire

Jan 3, 2022

04:10PM EST Acorda Therapeutics Appoints John Varian To Board Of Directors RTTNews

04:01PM EST John Varian Joins Acorda Therapeutics Board of Directors Business Wire

Nov 19, 2021

11:37AM EST Acorda Therapeutics Shares Quiet, See Large Spike In Volume; FDA AccessData.gov Listing For Co.'s New Drug Application For Dalfampridine Shows FDA Approved Benzinga

Nov 9, 2021

04:28PM EST Acorda Therapeutics Announces Agreement To Commercialize INBRIJA In Germany; Acorda Will Receive A 5M Upfront Payment, And Will Receive Additional Sales-based Milestones Benzinga

04:27PM EST Acorda Therapeutics Appoints Michael Gesser, M.B.A. As Chief Financial Officer Benzinga

04:25PM EST Acorda Therapeutics Q3 EPS $(1.43) Beats $(1.56) Estimate, Sales $31.46M Beat $30.57M Estimate Benzinga

04:01PM EST Acorda Therapeutics Announces Agreement to Commercialize INBRIJA(r) in Germany Business Wire

04:01PM EST Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team Business Wire

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Nov 8, 2021

09:57AM EST Earnings Outlook For Acorda Therapeutics Benzinga

Nov 2, 2021

07:00AM EDT Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021 Business Wire

Oct 5, 2021

10:51AM EDT Acorda Therapeutics US Patent & Trademark Office Abstract For Co.'s 'Carbonate prodrugs and methods of using the same' Benzinga

Sep 9, 2021

08:34AM EDT Acorda Therapeutics To Reduce Headcount; Names Lauren RTTNews

08:10AM EDT Acorda Therapeutics To Reduce Headcount By 15%, Sees $3 Mln Of Pre-tax Charges RTTNews

08:01AM EDT Acorda Therapeutics Announces Corporate Restructuring, Management Changes Business Wire

Aug 26, 2021

10:32AM EDT Return on Capital Employed Insights for Acorda Therapeutics Benzinga

Aug 6, 2021

07:56AM EDT Acorda Therapeutics Q2 GAAP EPS $(2.29), Adj. EPS $(1.87) Beats $(2.09) Estimate, Sales $31.79M Beat $29.94M Estimate Benzinga

07:56AM EDT CORRECTION: Acorda Thearpeutics Q2 Adj. EPS $(1.87), Beats $(2.09) Estimate Benzinga

Aug 5, 2021

04:38PM EDT Acorda Therapeutics Q2 EPS $(2.29) Misses $(2.09) Estimate, Sales $31.79M Beat $29.94M Estimate Benzinga

04:02PM EDT Acorda Therapeutics Reports Second Quarter 2021 Financial Results Business Wire

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Jul 30, 2021

04:01PM EDT Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021 Business Wire

Jul 27, 2021

11:13AM EDT Acorda Therapeutics Granted U.S. Patent Titled 'Methods for detecting cardiac damage' Benzinga

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

07:17AM EDT Acorda Therapeutics Shares Gains On Spain Distribution Pact For Parkinson's Med Benzinga

Jul 22, 2021

04:09PM EDT Acorda Therapeutics Announces Agreement to Commercialize INBRIJA in Spain Benzinga

Jun 17, 2021

11:48AM EDT UPDATE: HC Wainwright On Acorda: Attributes Upgrade To Co.'s Successful Maturity Of 2021 Convertible Notes, Management's Focus On Cost Containment Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 17, 2021 Benzinga

09:17AM EDT HC Wainwright & Co. Upgrades Acorda Therapeutics to Buy, Raises Price Target to $10 Benzinga

Jun 16, 2021

07:06AM EDT Acorda Therapeutics Reports Repayment Of Convertible Senior Notes RTTNews

07:00AM EDT Acorda Therapeutics Announces Repayment of Convertible Senior Notes Business Wire

Jun 1, 2021

03:04PM EDT Acorda Therapeutics Granted U.S. Patent Titled 'Water-soluble acetaminophen analogs' Benzinga

May 14, 2021

04:45PM EDT CORRECTION: Soros 13F Shows Stake In Acorda Therapeutics Notes, Not Common Stock Benzinga

04:44PM EDT Soros Fund Management 13F Shows New Stake In Acorda Therapeutics Benzinga

May 6, 2021

04:02PM EDT Acorda Therapeutics Sees FY21 AMPYRA Sales $75M-$85M Benzinga

04:01PM EDT Acorda Therapeutics Q1 EPS $(2.46) Beats $(2.54) Estimate, Sales $28.86M Beat $22.15M Estimate Benzinga

04:00PM EDT Acorda Therapeutics Reports First Quarter 2021 Financial Results Business Wire

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 29, 2021

04:30PM EDT Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021 Business Wire

Apr 12, 2021

07:00AM EDT Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of "A Taste for Life with Zarela?" Business Wire

Mar 8, 2021

05:44PM EST Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference Business Wire

Mar 4, 2021

04:05PM EST Acorda Sees FY21 AMPYRA Net Sales $75M-$85M Benzinga

04:04PM EST Acorda Therapeutics Q4 EPS $(2.50) Misses $(1.48) Estimate, Sales $38.16M Beat $34.00M Estimate Benzinga

04:01PM EST Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

04:07AM EST Earnings Scheduled For March 4, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 25, 2021

07:00AM EST Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021 Business Wire

Feb 19, 2021

07:06AM EST Acorda Therapeutics: David Lawrence Is Resigning From Company Effective Mid-March, 2021 RTTNews

07:00AM EST Acorda Therapeutics Announces Departure of Chief, Business Operations Business Wire

Feb 11, 2021

07:25AM EST Acorda Therapeutics Says Completes Sale Of Its Manufacturing Ops. In Chelsea, Massachusetts To Catalent RTTNews

07:00AM EST Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent Business Wire

Jan 20, 2021

04:14PM EST Acorda Therapeutics On Jan. 19, 2021, Received A Letter From Nasdaq, Notifying Company That It Had Regained Compliance With Listing Rule Benzinga

Jan 13, 2021

01:58PM EST Hearing Cowen Raises Acorda Therapeutics Price Target From $5 To $35/Share; Unconfirmed Benzinga

09:55AM EST Acorda Therapeutics, Inc. (ACOR) shares are rising on Wednesday morning trade as the company announced an agreement to sell INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent for $80 million in cash. RTTNews

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

07:12AM EST Acorda To Sell Its INBRIJAmanufacturing Operations In Chelsea, Massachusetts To Catalent For $80 Mln Cash RTTNews

07:12AM EST A Look Into Acorda Therapeutics's Debt Benzinga

07:09AM EST Acorda Therapeutics Announces Agreement To Sell Its INBRIJA Manufacturing Operations In Chelsea, Massachusetts To Catalent For $80M In Cash Benzinga

07:08AM EST Acorda Enters At The Market Offering Agreement With H.C. Wainwright Of Up To $15.25M Benzinga

07:07AM EST Acorda Therapeutics Announces Corporate Restructuring, Will Reduce Ardsley, Waltham And Field Headcount By 16% Benzinga

07:06AM EST UPDATE: In Connectoin With Sale, Acorda And Catalent Have Entered Into A Long-term Global Supply Agreement Under Which Catalent Will Manufacture And Package INBRIJA For Acorda Benzinga

07:05AM EST Acorda Therapeutics Announces Agreement To Sell Its INBRIJA Manufacturing Operations In Chelsea, Massachusetts To Catalent For $80M In Cash Benzinga

07:00AM EST Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA(r), Corporate Restructuring, and Enters into "At The Market" Offering Agreement Business Wire

Jan 12, 2021

04:07PM EST Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care Conference Business Wire

Jan 11, 2021

04:20PM EST Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual Conference Business Wire

Dec 31, 2020

04:19PM EST Acorda Therapeutics Announces Completion of One-for-Six Reverse Stock Split Business Wire

Dec 21, 2020

06:54AM EST Acorda Therapeutics Inc Announces Co. Intends To Conduct A Reverse Stock Split At A Ratio Of 1-for-6 Benzinga

Dec 2, 2020

02:14PM EST Acorda Therapeutics Granted European Patent 'USE OF GGF2 TO TREAT NEUROPATHIC PAIN UPON PERIPHERAL NERVE INJURY' Benzinga

Nov 23, 2020

10:24AM EST 5 Value Stocks To Watch In The Healthcare Sector Benzinga

Nov 16, 2020

09:48AM EST A Look Into Healthcare Sector Value Stocks Benzinga

Nov 4, 2020

05:56AM EST What's moving these stocks in the pre-market hours today? RTTNews

Nov 3, 2020

04:17PM EST Acorda Therapeutics: Q3 Earnings Insights Benzinga

04:01PM EST Acorda Therapeutics Q3 EPS $(0.23) Beats $(0.31) Estimate, Sales $53.09M Beat $29.29M Estimate Benzinga

04:00PM EST Acorda Reports Third Quarter 2020 Financial Results Business Wire

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

04:07AM EST Earnings Scheduled For November 3, 2020 Benzinga

Nov 2, 2020

10:17AM EST Preview: Acorda Therapeutics's Earnings Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 27, 2020

07:00AM EDT Acorda Third Quarter 2020 Update: Webcast/Conference Call Scheduled for November 3, 2020 Business Wire

Oct 20, 2020

02:34PM EDT Mid-Afternoon Market Update: Dow Rises 1%; Aptinyx Shares Spike Higher Benzinga

12:12PM EDT Mid-Day Market Update: Cleveland BioLabs Jumps On Merger News; Isoray Shares Slide Benzinga

11:17AM EDT Why Acorda's Stock Is Trading Higher Today Benzinga

Oct 19, 2020

04:49PM EDT UPDATE: Acorda Says Will Receive Payment From Biogen Based On Biogen's Ex-US Net Sales Of Fampyra Exceeding $100M For 4 Consecutive Quarters Ending Q3'20 Benzinga

Sep 17, 2020

07:01AM EDT Aravive Appoints Michael W. Rogers to Board of Directors GlobeNewswire Inc

Sep 11, 2020

07:15AM EDT Acorda Therapeutics S-3 Shows Registration For ~158.4M Share Common Stock Offering By Selling Shareholders Benzinga

Aug 4, 2020

04:21PM EDT Acorda Therapeutics: Q2 Earnings Insights Benzinga

04:01PM EDT Acorda Therapeutics Q2 EPS $(0.35) Beats $(0.48) Estimate, Sales $33.62M Beat $27.50M Estimate Benzinga

04:00PM EDT Acorda Reports Second Quarter 2020 Financial Results Business Wire

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 31, 2020

12:45PM EDT Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders Business Wire

Jul 28, 2020

07:00AM EDT Acorda Second Quarter 2020 Update: Webcast/Conference Call Scheduled for August 4, 2020 Business Wire

Jul 14, 2020

04:08PM EDT Acorda Therapeutics Says Received US Income Tax Refund From Internal Revenue Service Of Approximately $12.7M Benzinga

Share